Outlook Therapeutics Investor Relations Material
Latest events
Status Update
Outlook Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Outlook Therapeutics Inc
Access all reports
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and launching innovative treatments for ocular diseases. The company is currently working on ONS-5010 / LYTENAVA™ (bevacizumab-vikg), aiming to make it the first FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). The company is headquartered in Iselin, New Jersey, and its shares are listed on the Nasdaq.
Key slides for Outlook Therapeutics Inc
Corporate Presentation
Outlook Therapeutics Inc
Corporate Presentation
Outlook Therapeutics Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
OTLK
Country
🇺🇸 United States